AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03036449 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education program for NICU caregivers.
Description: Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation.....~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists...
Study NCT02713789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)
Study NCT02713789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBS-20% sucrose)
Study NCT00891696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine
Study NCT00891696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine
Study NCT00891696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside
Description: Variable rate for 3 hours
Study NCT00891163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)
Description: 30 minute applicable on antecubital fossa
Study NCT00891163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: placebo
Study NCT01921634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified Pathologic Analysis
Study NCT04186728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium glycinate
Description: Daily magnesium capsule.
Study NCT00891696 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction cuff
Description: Blood flow restriction for 5 minutes after the second biopsy
Study NCT00891696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction cuff
Description: Blood flow restriction for 5 minutes after the second biopsy
Study NCT04186728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium glycinate
Description: Daily magnesium capsule.
Study NCT04066530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-203
Description: AD-203 administered two times daily for two weeks
Study NCT04066530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucosta tab.
Description: Mucosta tab. administered three times daily for two weeks
Study NCT01770743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
Study NCT01770743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Study NCT01366573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
Study NCT01366573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01366573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03810846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking football exercise program
Description: Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
Study NCT02073162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Major Abdominal Surgery
Description: •All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
Study NCT02073162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major Abdominal Surgery
Description: •All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
Study NCT01658085 — intervention group
Intervention type: DEVICE
Intervention: ACE14S
Description: Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
Study NCT01658085 — intervention group
Intervention type: DEVICE
Intervention: HARMONIC FOCUS®
Description: Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
Study NCT03115372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend CRC education session
Study NCT03115372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend healthy nutrition session
Study NCT03115372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive CRC screening brochure
Study NCT03115372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03115372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03115372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone reminder about CRC screening
Study NCT03115372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive telephone reminder about healthy nutrition
Study NCT03404635 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban as standard of care for VTE
Study NCT01816425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic partial denture
Study NCT01816425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoCr partial denture
Study NCT04186728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily placebo capsule.
Study NCT04186728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo capsule.
Study NCT03404635 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban as standard of care for VTE
Study NCT00698035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Cream
Description: 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
Study NCT00698035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estring
Description: 2mg ring inserted vaginally once every 12 weeks
Study NCT04673604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of ocular surface staining (Oxford score 0-15 scale)
Description: Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
Study NCT04673604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of ocular surface staining (Oxford score 0-15 scale)
Description: Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
Study NCT04673604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mean diurnal intraocular pressure-lowering
Description: At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
Study NCT04673604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mean diurnal intraocular pressure-lowering
Description: At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
Study NCT01824693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HCT
Study NCT01824693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01824693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01824693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01824693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01824693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01824693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT01824693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01824693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02992834 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-2 pre-treated CD19 cells
Description: IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
Study NCT02992834 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-7/IL-15 pre-treated CD19 cells
Description: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
Study NCT04403529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Formulation
Description: The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption.
Study NCT04403529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formulation
Description: Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption.
Study NCT01691287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Michael Method
Study NCT04818528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy and Routine Physical Therapy
Description: Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
Study NCT04818528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
Study NCT01677507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variation in eye pressure response to timolol and latanoprost treatment
Description: Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
Study NCT01677507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variation in eye pressure response to timolol and latanoprost treatment
Description: Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
Study NCT04172311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: Modified Atkins diet is a type of ketogenic diet which is less restrictive
Study NCT04172311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
Study NCT02452112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Lidocaine patch
Description: 5% Lidocaine patch to be placed on the site of pain
Study NCT02452112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch to be placed on the site of pain
Study NCT03999541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-all policy
Description: A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
Study NCT03409419 — intervention group
Intervention type: DRUG
Intervention: [18F] CFA
Description: pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
Study NCT00515580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Sutures for Obstructive Sleep Apnea
Description: Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
Study NCT04372342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine
Description: Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
Study NCT04372342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: remifentanil
Study NCT02802878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Training using Electrodes and Joint Motion Sensors
Description: Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group.
Study NCT03217396 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: lumbar puncture performed to detect OCB for diagnostic purposes
Study NCT02802878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic Training with Isokinetic Dynamometer
Description: Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
Study NCT02665078 — intervention group
Intervention type: OTHER
Intervention: Thoracoscopic Ultrasound
Description: We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
Study NCT03082053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varlitinib
Description: IMP
Study NCT03082053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Companion Medication
Study NCT03261765 — intervention group
Intervention type: OTHER
Intervention: Assessment of adhesions
Description: Modified Nair scoring system
Study NCT02302313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 laser and ANI monitor
Description: Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
Study NCT02945800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
Study NCT02945800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m\^2 intravenously (IV)
Study NCT04077736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
Study NCT04624308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
Study NCT00503425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab [MabThera/Rituxan]
Description: 1000 mg IV on days 1 and 15
Study NCT04382027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 + vitamin K2 (monoacylglycerol form)
Description: The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments.
Study NCT04382027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 + vitamin K2 (ethyl ester)
Description: The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments.
Study NCT02370472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tool developed using cameras and a computer
Description: cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
Study NCT03116997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine+glycopyrrolate
Description: At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
Study NCT01686958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-Guided Transurethral US Ablation of Prostate Tissue
Description: The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
Study NCT02858973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q203
Study NCT02858973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03116997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: At the conclusion of surgery neuromuscular blockade reversed with sugammadex
Study NCT01957787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Application of extremely cold temperatures to the identified tumor(s).
Study NCT01963754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implants in Posterior Mandible
Description: Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations